Long-Term Outcome of Chronic Hepatitis B-Histological Score and Viral Genotype Are Important Predictors of Hepatocellular Carcinoma

Overview

Journal J Viral Hepat

Date 2025 Jan 29

PMID 39878776

Authors

Anders Eilard

Johan Ringlander

Maria E Andersson

Staffan Nilsson

Gunnar Norkrans

Magnus Lindh

Affiliations

Soon will be listed here.

Abstract

Current guidelines to prevent hepatocellular carcinoma (HCC) by chronic hepatitis B virus (HBV) infection are based on risk assessments that include age, sex, and virological and biochemical parameters. The study aim was to investigate the impact of predictive markers on long-term outcomes. The clinical outcomes of 100 patients with chronic hepatitis B were investigated 30 years after a baseline assessment that included liver biopsy. A favourable outcome-HBsAg loss or HBeAg-negative infection (ENI; previously termed 'inactive carrier')-was observed in 74% of all patients, whereas 7% developed HCC. HBsAg loss was observed in 75% of patients with genotype A, compared with 42%, 33% and 0% with genotypes D, B and C, respectively (p < 0.0001). HCC developed in 3 patients (33%) with genotype C as compared with 3 (17%), 1 (2%) and 0 patients with genotypes B, D and A, respectively (p < 0.0001). In multiple logistic regression analysis, both HBsAg loss and HCC were associated with HBV genotype and baseline HBV DNA level, and HCC also with histological score. The results suggest that genotyping and histological assessment may improve outcome prediction and help decisions about HCC screening, particularly in populations with HBV-infected individuals of mixed geographic origin.

References

Kim B, Revill P, Ahn S . HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B. Antivir Ther. 2011; 16(8):1169-86. DOI: 10.3851/IMP1982. View

Park H, Kim S . Imaging Modalities for Hepatocellular Carcinoma Surveillance: Expanding Horizons beyond Ultrasound. J Liver Cancer. 2023; 20(2):99-105. PMC: 10035675. DOI: 10.17998/jlc.20.2.99. View

Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H . Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2012; 58(1):98-107. DOI: 10.1002/hep.26180. View

Manno M, Camma C, Schepis F, Bassi F, Gelmini R, Giannini F . Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology. 2004; 127(3):756-63. DOI: 10.1053/j.gastro.2004.06.021. View

Yang H, Yeh S, Chen P, Iloeje U, Jen C, Su J . Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst. 2008; 100(16):1134-43. PMC: 2518166. DOI: 10.1093/jnci/djn243. View

Simonetti J, Bulkow L, McMahon B, Homan C, Snowball M, Negus S . Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology. 2010; 51(5):1531-7. DOI: 10.1002/hep.23464. View

Chen C, Yang H, Su J, Jen C, You S, Lu S . Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006; 295(1):65-73. DOI: 10.1001/jama.295.1.65. View

Kim J, Kim Y, Lee M, Jun B, Kim T, Suk K . Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy. J Hepatol. 2018; 69(5):1066-1073. DOI: 10.1016/j.jhep.2018.07.018. View

Kew M . Hepatocellular carcinoma in African Blacks: Recent progress in etiology and pathogenesis. World J Hepatol. 2010; 2(2):65-73. PMC: 2999270. DOI: 10.4254/wjh.v2.i2.65. View

10.

Wong V, Chan S, Mo F, Chan T, Loong H, Wong G . Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol. 2010; 28(10):1660-5. DOI: 10.1200/JCO.2009.26.2675. View

11.

Kao J, Chen P, Lai M, Chen D . Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology. 2000; 118(3):554-9. DOI: 10.1016/s0016-5085(00)70261-7. View

12.

de Franchis R, Meucci G, Vecchi M, Tatarella M, Colombo M, Del Ninno E . The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med. 1993; 118(3):191-4. DOI: 10.7326/0003-4819-118-3-199302010-00006. View

13.

Sanchez-Tapias J, Costa J, Mas A, Bruguera M, Rodes J . Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology. 2002; 123(6):1848-56. DOI: 10.1053/gast.2002.37041. View

14.

Batoctoy K, Tseng T, Kao J, Quiza F, Garcia Sr L, Lao-Tan J . HBV/A and HBV/C genotype predominance among patients with chronic hepatitis B virus infection in Cebu City, Philippines. Hepatol Int. 2011; 5(3):774-81. DOI: 10.1007/s12072-011-9263-1. View

15.

Iloeje U, Yang H, Su J, Jen C, You S, Chen C . Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006; 130(3):678-86. DOI: 10.1053/j.gastro.2005.11.016. View

16.

Terrault N, Bzowej N, Chang K, Hwang J, Jonas M, Murad M . AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2015; 63(1):261-83. PMC: 5987259. DOI: 10.1002/hep.28156. View

17.

Lindh M, Horal P, Dhillon A, Norkrans G . Hepatitis B virus DNA levels, precore mutations, genotypes and histological activity in chronic hepatitis B. J Viral Hepat. 2000; 7(4):258-67. DOI: 10.1046/j.1365-2893.2000.00236.x. View

18.

Park H, Jang H, Kim S, Lee S, Won H, Byun J . Non-enhanced magnetic resonance imaging as a surveillance tool for hepatocellular carcinoma: Comparison with ultrasound. J Hepatol. 2019; 72(4):718-724. DOI: 10.1016/j.jhep.2019.12.001. View

19.

Sung J, Tsoi K, Wong V, Li K, Chan H . Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther. 2008; 28(9):1067-77. DOI: 10.1111/j.1365-2036.2008.03816.x. View

20.

Yuen M, Yuan H, Wong D, Yuen J, Wong W, Chan A . Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut. 2005; 54(11):1610-4. PMC: 1774768. DOI: 10.1136/gut.2005.065136. View